Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTimal: Tirilizumab + Chemo in Oral SCC
NCT06470217Phase 2Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tirilizumab in oral squamous cell carcinoma (OSCC), sponsored by Shanghai Ninth People's Hospital. Started Jun 2024; status: recruiting.
02
Drugs
tirilizumab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT06470217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470217.